当前位置: X-MOL 学术BMC Psychiatry › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Feasibility and outcome of metacognitive therapy for major depressive disorder: a pilot study
BMC Psychiatry ( IF 4.4 ) Pub Date : 2020-11-26 , DOI: 10.1186/s12888-020-02976-4
Lotta Winter , Ulrich Schweiger , Kai G. Kahl

Several studies have shown the effectiveness of Metacognitive Therapy (MCT) in treating different mental disorders. Most of these studies were performed in English speaking countries using the original English version of the manual. Our study aimed to examine the feasibility of the translated MCT manual in a sample of German patients with major depressive disorder. Twenty outpatients (6 male, 14 female, mean age 42.1y) with major depressive disorder were included. The main outcome was drop-out rate and satisfaction with the treatment; secondary outcomes were changes in metacognitive beliefs assessed with the metacognitive questionnaire 30 (MCQ-30), and symptom reduction measured with the Beck Depression Inventory-2 sum score (BDI-2). No drop-outs during the treatment and the follow-up phase were observed. Patients and therapists were highly satisfied with MCT treatment. The MCQ-30 significantly declined over the treatment course, paralleled by a significant reduction of the BDI-2 sum scores (from 29 ± 8.6 at T0 to 8.4 ± 9.6 at the end of treatment). The average treatment duration was 10 ± 4 sessions. Applying the German version of the manual for Metacognitive Therapy proved to be feasible in the treatment of depressed patients in an outpatient setting. The treatment was well tolerated by German patients. Outcome in terms of reduction of depressive symptoms was good. Remarkable is the comparably short treatment duration which should be investigated further in future studies. German Clinical Trials Register (DRKS): DRKS00023644, 17.11.2020 (retrospectively registered).

中文翻译:

重症抑郁症的元认知治疗的可行性和结果:一项初步研究

多项研究表明,元认知疗法(MCT)在治疗各种精神障碍方面的有效性。这些研究大多数是在使用英语原始版本的手册的英语国家进行的。我们的研究旨在检查MCT手册翻译版本在德国重度抑郁症患者中的可行性。包括20例重度抑郁症的门诊患者(男6例,女14例,平均年龄42.1y)。主要结果是辍学率和对治疗的满意程度。次要结果是通过元认知问卷30(MCQ-30)评估的元认知信念的变化,以及通过Beck Depression Inventory-2总评分(BDI-2)衡量的症状减轻。在治疗和随访阶段未观察到脱落。患者和治疗师对MCT治疗非常满意。MCQ-30在整个治疗过程中显着下降,同时BDI-2总和得分显着降低(从T0的29±8.6降至治疗结束时的8.4±9.6)。平均治疗时间为10±4个疗程。实践证明,应用德文版的元认知治疗手册在门诊治疗抑郁症患者中是可行的。德国患者对治疗的耐受性良好。就减轻抑郁症状而言,结果良好。值得注意的是相对较短的治疗时间,应在以后的研究中进一步研究。德国临床试验注册簿(DRKS):DRKS00023644,2020年11月17日(追溯注册)。与此同时,BDI-2总和分数显着降低(从T0的29±8.6降至治疗结束时的8.4±9.6)。平均治疗时间为10±4个疗程。实践证明,应用德文版的元认知治疗手册在门诊治疗抑郁症患者中是可行的。德国患者对治疗的耐受性良好。就减轻抑郁症状而言,结果良好。值得注意的是相对较短的治疗时间,应在以后的研究中进一步研究。德国临床试验注册簿(DRKS):DRKS00023644,2020年11月17日(追溯注册)。与此同时,BDI-2总和分数显着降低(从T0的29±8.6降至治疗结束时的8.4±9.6)。平均治疗时间为10±4个疗程。实践证明,应用德文版的元认知疗法手册在门诊治疗抑郁症患者中是可行的。德国患者对治疗的耐受性良好。就减轻抑郁症状而言,结果良好。值得注意的是相对较短的治疗时间,应在以后的研究中进一步研究。德国临床试验注册簿(DRKS):DRKS00023644,2020年11月17日(追溯注册)。实践证明,应用德文版的元认知治疗手册在门诊治疗抑郁症患者中是可行的。德国患者对治疗的耐受性良好。就减轻抑郁症状而言,结果良好。值得注意的是相对较短的治疗时间,应在以后的研究中进一步研究。德国临床试验注册簿(DRKS):DRKS00023644,2020年11月17日(追溯注册)。实践证明,应用德文版的元认知疗法手册在门诊治疗抑郁症患者中是可行的。德国患者对治疗的耐受性良好。就减轻抑郁症状而言,结果良好。值得注意的是相对较短的治疗时间,应在以后的研究中进一步研究。德国临床试验注册簿(DRKS):DRKS00023644,2020年11月17日(追溯注册)。
更新日期:2020-11-27
down
wechat
bug